Autophagy and inflammation are two processes vital for immune cells to perform their functions. Their proper interplay upon signal is pivotal for proper response to stress. The stress kinase p38α MAPK in microglia senses inflammatory cue LPS, directly phosphorylates ULK1, relieves the autophagic inhibition on the inflammatory machinery, and thus allows for a full immune response.
Recent studies have highlighted the cross-talk between autophagy and inflammation. Increasing evidences show that autophagy plays important roles in both innate and adaptive immunity through eliminating invading pathogens, regulating innate pathogen recognition, contributing to antigen presentation via major histocompatibility complex class I/II molecules, and controlling B cell and T cell development and survival [6, 7] . It is also becoming increasingly clear that immune signaling cascades are subject to regulation by autophagy, and a return to homeostasis following a robust immune response is critically dependent on autophagy. Autophagy dysfunction contributes to the pathogenesis of various inflammation-related disorders [8] . On the other hand, more and more studies indicate that a variety of immune mediators either induce or repress autophagy. For example, it is well established that in general Th1 cytokines, including IFN-γ, TNF-α, IL-1, IL-2, IL-6 and TGF-β, induce autophagy while the classical Th2 cytokines, including IL-4, IL-10 and IL-13, have the effects of autophagy inhibition [9] .
Lipopolysaccharide (LPS), a gram-negative bacteria outer-wall component, has been shown to inhibit autophagy and induce microglia activation through binding to its cognate receptor complex-Toll like receptor 4 (TLR4) on microglia surface [6] . However, the signaling mechanisms that lead to LPS-induced autophagy reduction and whether such a reduction is required for activating inflammation in microglia remain unknown. The stress kinase p38α mitogen-activated protein kinase (p38α MAPK) plays a central role in inflammation and is the master kinase for activation of NOD-like receptor protein 3 (NLRP3) inflammasome in microglia [10] . The p38α MAPK has been the subject of extensive efforts in both basic research and drug discovery for the treatment of a wide range of diseases. Inhibitors of p38 MAPK are currently in development for the clinical trial for several inflammatory diseases such as Crohn's disease and rheumatoid arthritis [11, 12] . Also of note, a key initial event in autophagy is the formation of the autophagosome, a unique double-membrane organelle that engulfs the cytosolic cargo destined for degradation. This step is mediated by the serine/ threonine protein kinase unc-51-like kinase 1 (ULK1), which functions in a complex with at least three other protein partners, focal adhesion kinase family interacting protein of 200 kDa (FIP200), autophagy-related protein 13 (ATG13), and ATG101. A plethora of different upstream pathways, such as nutrients sensing by AMPK and mTOR, converge on ULK1, suggesting that this complex acts as a signaling node and convert multiple cellular inputs into tight regulation of autophagosome formation [13, 14] .
Our recent work showed that p38α MAPK plays a direct and essential role in relieving the inhibitory autophagic controlling of inflammation in response to inflammatory signals [15] . We found that p38α MAPK interacts with ULK1 in microglia. Upon LPS stimulation of TLR4 on microglia surface, activated p38α MAPK directly phosphorylates ULK1, the serine/threonine kinase in the initiation complex of the autophagic cascade, in primary microglia and in animal brain. Phosphorylation by p38α MAPK inhibits ULK1 kinase activity and disrupts its interaction with a key partner ATG13 in the autophagy initiation complex, and reduces the level and flux of autophagy. This p38α MAPK/ULK1-induced autophagy inhibition is necessary for LPS-induced NLRP3 inflammasome activity, subsequent processing of pro-interleukin-1β (pro-IL-1β) into IL-1β by caspase-1, and microglia full activation in culture and in mouse brain (Figure 1) . Thus, our findings establish a mechanism that functions to relieve the immune suppressive activity of She et al. Page 2 autophagy upon stimulation and allows the full induction of inflammatory process during microglial activation. This mechanism may play an important role in regulating innate immune response in the central nervous system.
It should be noted that many previous studies have reported that LPS-induced macrophage activation and secretion of inflammatory cytokines/chemokines is accompanied by enhanced autophagy activity [16] . In addition, this is also mediated through TLR4 and p38 MAPK as inhibition of either TLR4 or p38 MAPK blocks LPS-induced autophagy increase and macrophage activation [17, 18] . This is in clear contrast to the finding that autophagy is significantly reduced under both acute and chronic inflammatory conditions in microglia.
For example, induction of autophagy activity by rapamycin has been shown to inhibit microglia over-activation, reduce the secretion of pro-inflammatory mediators, and provide protection against various insults in several animal models of neurodegenerative diseases including Alzheimer's disease and Parkinson's disease [19] . It seems that autophagy plays different roles in macrophage and microglia in their inflammatory response. The molecular mechanisms underlie this sharp difference warrants further investigation. In our work, we notice that in microglia cell line BV2 cells, LPS-induced p38α MAPK activation leads to a strong ULK1 phosphorylation. But in macrophage derived RAW264.7 cells, p38α MAPK activity and ULK1 phosphorylation appear to be uncoupled. In addition, previous report showed that LPS induces a robust Nrf2-dependent transcription of p62, a key autophagy adaptor protein, in macrophage [20] . While under our experimental condition, LPS has no effect on the transcription of p62 in microglia. These results further highlight the inherent differences among immune cells derived from different origins.
Accumulating evidence suggests that microphage and microglia acquire different activation states to modulate their cellular functions under different contexts [21] . Upon activation to the M1 phenotype, macrophage and microglia release pro-inflammatory cytokines and neurotoxic molecules promoting inflammation and cytotoxic responses. In contrast, when adopting the M2 phenotype, they secrete anti-inflammatory gene products and trophic factors that promote repair and regeneration to restore homeostasis [22] . The M1 and M2 states can coexist at the same time in different population of cells around the same lesion site. In addition, under certain situations, a single cell can display both M1 and M2 phenotypes simultaneously. Intriguing and challenging questions are how these apparent opposite activation states are regulated and whether p38α MAPK-ULK1 axis plays a role during the switch of the two states in microglia. Furthermore, very little is known about the switch of microglia activation state during disease progress. A better understanding is essential for developing more efficient protective agents. p38α MAPK-ULK1 axis may offer a new target to modulate microglia activation state and suppress their deleterious proinflammatory neurotoxicity as a therapeutic approach for the treatment of inflammatory and neurodegenerative diseases.
In conclusion, autophagy and inflammation are two key intertwined cellular processes that act together to modulate functions of innate immune cells. Their interplay may be distinctly regulated in microglia and macrophage. A better understanding of the regulatory mechanism of immune cell activation should provide insight for designing more sensible therapeutic strategies for the many immune-related diseases.
